Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Lin

Showing results (1-10 of 136) with videos related to

Pageof 14
Sort By:
Urologic Oncology|November 6, 2016
Commentary on "Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer." Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM, University of Washington-Urology, Seattle, WA. Nat Commun 2015; 6:6605Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer." Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA, University of Washington-Urology, Seattle, WA. Nat Commun 2014; 5:5383Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS, University of Washington-Urology, Seattle, WA. Nature 2015; 520(7547):353-7Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1." Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY, University of Washington-Urology, Seattle, WA. Lancet Oncol 2014; 15(13):1469-80Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer." Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR, PRACTICAL Consortium, Australian Prostate Cancer BioResource, Spurdle AB, Clements JA, Park JY, Batra J, University of Washington-Urology, Seattle, WA. Cancer Discov 2015; 5(4):368-79Daniel Lin
Seminars in Thoracic and Cardiovascular Surgery|December 3, 2014
The current status of neoadjuvant therapy for esophageal cancerDaniel Lin, Lawrence Leichman
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder" Maintenance Treatment in Bipolar DisorderMauricio Tohen, Daniel Lin
World Journal of Gastroenterology|November 18, 2015
Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic targetDaniel Lin, Jennifer Wu
Journal of Gastrointestinal Oncology|November 18, 2024
Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?Ali Raza Shaikh, Daniel Lin
Pharmacology, Biochemistry, and Behavior|March 13, 2002
Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-mazeDaniel Lin, Loren H Parsons
Pageof 14

Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
Urologic Oncology|November 6, 2016
Commentary on "Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer." Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM, University of Washington-Urology, Seattle, WA. Nat Commun 2015; 6:6605Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer." Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA, University of Washington-Urology, Seattle, WA. Nat Commun 2014; 5:5383Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS, University of Washington-Urology, Seattle, WA. Nature 2015; 520(7547):353-7Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1." Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY, University of Washington-Urology, Seattle, WA. Lancet Oncol 2014; 15(13):1469-80Daniel Lin
Urologic Oncology|November 6, 2016
Commentary on "A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer." Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR, PRACTICAL Consortium, Australian Prostate Cancer BioResource, Spurdle AB, Clements JA, Park JY, Batra J, University of Washington-Urology, Seattle, WA. Cancer Discov 2015; 5(4):368-79Daniel Lin
Seminars in Thoracic and Cardiovascular Surgery|December 3, 2014
The current status of neoadjuvant therapy for esophageal cancerDaniel Lin, Lawrence Leichman
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder" Maintenance Treatment in Bipolar DisorderMauricio Tohen, Daniel Lin
World Journal of Gastroenterology|November 18, 2015
Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic targetDaniel Lin, Jennifer Wu
Journal of Gastrointestinal Oncology|November 18, 2024
Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?Ali Raza Shaikh, Daniel Lin
Pharmacology, Biochemistry, and Behavior|March 13, 2002
Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-mazeDaniel Lin, Loren H Parsons
Pageof 14